UCB Showcases Groundbreaking Epilepsy Research at International Epilepsy Congress

UCB, a leading global biopharmaceutical company, recently revealed its commitment to advancing the care of individuals affected by epilepsy at the 2025 International Epilepsy Congress (IEC) in Lisbon, Portugal. The company's presentation featured an impressive collection of 26 scientific abstracts, including two significant oral presentations, navigating the complexities surrounding developmental and epileptic encephalopathies (DEEs) and other epilepsy syndromes.

Commitment to Epilepsy Research

Dimitrios Bourikas, UCB’s Global Medical Head of DEE and Epilepsy, expressed enthusiasm at the congress, stating, "At UCB, we are committed to driving improvements in all aspects of care for people living with epilepsies and severe epileptic conditions." The data presented reflect a detailed investigation of real-world challenges faced by patients, caregivers, and healthcare professionals.

Overview of Key Data Presented

Among the highlights of UCB’s presentations are findings from an open-label extension study on FINTEPLA® (fenfluramine), which emphasized its long-term safety and efficacy in children and adults diagnosed with Dravet syndrome and Lennox-Gastaut syndrome. This study encompassed 412 patients and showcased sustained benefits and no unexpected side effects over an extended duration of treatment.

Furthermore, UCB centered its research on critical aspects such as the challenges of diagnosing DEEs in adult care settings and assessing the impacts of unpredictable seizures on caregivers. Notably, a survey indicated that nearly 50% of caregivers experienced significant disruptions in daily life due to high rates of unpredictable seizures and disruptive behaviors, affirming the pressing need for enhanced support mechanisms.

A qualitative study delved into the barriers faced by adults in identifying DEEs, illuminating the stark contrast between diagnosis and treatment experiences in children versus adults. Findings suggested a need for improved diagnostic practices that could lead to better holistic care and a reduction in patient hospitalization rates.

Focus on Prolonged Seizures

UCB’s research also covered the definition and prevalence of prolonged seizures, which has remained a real concern for those living with epilepsy. A noteworthy segment of data focused on the experiences of caregivers, detailing the anxiety and prevalence of emergency situations triggered by prolonged seizures, often requiring immediate medical attention.

Innovative studies characterizing the patient population suffering from prolonged seizures revealed unmet needs and highlighted the profound impact these seizures have on quality of life. UCB aims to guide clinical approaches that could minimize the risk of such events and foster better management in outpatient settings.

Enhancing Diagnosis of Lennox-Gastaut Syndrome

A significant portion of UCB’s exploration revolved around Lennox-Gastaut syndrome (LGS), where the unpredictable array of symptoms poses diagnostic challenges. Experts from several countries collaborated on the development of a straightforward checklist designed for non-specialists to assist in the identification of LGS, using criteria developed by the International League Against Epilepsy.

Educational Symposium: Time Matters

Another key event was UCB's symposium on September 1, titled “Time matters in developmental and epileptic encephalopathies,” which aimed to enhance awareness of DEEs' impacts beyond seizure management. The session focused on the improvement of diagnosis and treatment journeys and the elimination of systemic barriers that hinder effective patient outcomes.

Conclusion

UCB continues to evolutionarily position itself at the forefront of epilepsy research and medication, paving the way for innovative solutions that cater to the actual needs of the epilepsy community. With continued dedication to understanding the complexities surrounding these conditions, UCB is committed to improving the lives of patients worldwide. As the company evolves, it remains focused on influencing positive changes in patient care, research methodologies, and therapeutic advancements against the backdrop of real-world challenges faced by both patients and their caregivers.